The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SWKH | +27.57% | +40.69% | +7.06% | -99% |
| S&P | +12.57% | +87.93% | +13.44% | +414% |
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company offers capital and investments in life science companies, institutions, and inventors. It operates through the Finance Receivables and Pharmaceutical Development segments. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions, and investors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.32M | -0.9% |
| Gross Profit | $10.14M | 6.6% |
| Gross Margin | 98.26% | 6.9% |
| Market Cap | $176.74M | 4.4% |
| Market Cap / Employee | $19.64M | 166.9% |
| Employees | 9 | 0.0% |
| Net Income | $8.78M | 153.2% |
| EBITDA | $9.56M | 37.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.21M | -40.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $31.92M | 2.2% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.44% | 3.8% |
| Return On Invested Capital | 5.15% | -1.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.52M | -91.7% |
| Operating Free Cash Flow | $0.87M | -86.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 13.50 | 11.77 | 10.41 | 7.82 | -58.11% |
| Price to Book | 0.54 | 0.58 | 0.62 | 0.72 | 19.52% |
| Price to Sales | 4.14 | 4.49 | 3.97 | 3.90 | -19.98% |
| Price to Tangible Book Value | 0.54 | 0.58 | 0.62 | 0.72 | 19.43% |
| Price to Free Cash Flow TTM | 10.70 | 9.37 | 8.54 | 7.98 | -33.61% |
| Enterprise Value to EBITDA | 19.02 | 40.74 | 29.22 | 20.71 | -36.95% |
| Free Cash Flow Yield | 9.3% | 10.7% | 11.7% | 12.5% | 50.63% |
| Return on Equity | 5.1% | 6.4% | 6.6% | 8.5% | 105.00% |
| Total Debt | $37.65M | $31.57M | $32.03M | $31.92M | 2.17% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
